📋 Why Verification Matters When Sourcing from India
India supplies over 20% of the world’s generic medicines by volume (GTRI, May 2026) and 60% of global vaccine demand. For international buyers — distributors, hospitals, pharmacies, and procurement agencies — the cost savings are significant (typically 80–90% vs. branded equivalents). But quality varies by facility. A systematic verification process protects your supply chain and patients.
🏛️ Core Regulatory Authorities to Know
- CDSCO (Central Drugs Standard Control Organization) — India’s national drug regulator. Approves manufacturing licenses (Form 25/28), new drugs, and export NOCs.
- State Drug Controllers — Issue manufacturing licenses and WHO-GMP certificates at the state level. Each state has its own portal.
- Pharmexcil — Export promotion council. Issues RCMC (Registration-Cum-Membership Certificate) confirming export eligibility.
- DGFT (Directorate General of Foreign Trade) — Issues IEC (Import Export Code) mandatory for all cross-border trade.
✅ 10-Point Manufacturer Verification Checklist
Before placing an order, confirm each item below. Request documents directly from the manufacturer — legitimate suppliers provide them routinely.
1. CDSCO Manufacturing License (Form 25/28)
What: License to manufacture drugs for sale/distribution.
Verify: Check the state drug controller portal (e.g., Karnataka FDA, Maharashtra FDA, Gujarat FDCA). License must be current and match the facility address.
2. WHO-GMP Certificate
What: Good Manufacturing Practices certificate issued by state FDA after inspection, valid 3 years.
Verify: Certificate must show scope (which products/sections), issue date, and validity. Cross-reference with WHO prequalified list at extranet.who.int/prequal.
3. COPP (Certificate of Pharmaceutical Product)
What: WHO-format certificate confirming the product is licensed in India and the manufacturer complies with GMP. Required by most importing countries.
Verify: Must be product-specific, issued by the state drug controller, and current (typically valid 2–3 years).
4. USFDA / EMA / PMDA / TGA Inspection History
What: Inspection records from stringent regulatory authorities (SRA).
Verify: Check FDA Drugs@FDA (establishment inspection reports), EMA GMP compliance, PMDA, TGA. A clean inspection history (no OAI/Warning Letters) is a strong quality signal.
5. Pharmexcil RCMC
What: Registration-Cum-Membership Certificate confirms the company is an eligible exporter.
Verify: Check validity on Pharmexcil portal or request a copy. Not a quality certificate per se, but confirms legitimate export status.
6. Batch-Specific Certificate of Analysis (CoA)
What: QC test results for each batch: assay, impurities, dissolution, microbial limits, heavy metals.
Verify: Demand CoA for every batch. Cross-check against pharmacopeial specs (IP/USP/EP). Look for: batch number, manufacturing/expiry dates, analyst signatures, QC lab stamp.
7. Stability Data (Real-Time & Accelerated)
What: Evidence the product remains within specs throughout shelf life under recommended storage conditions.
Verify: Manufacturer should provide stability protocol and summary data (ICH Q1A). Critical for products with cold-chain requirements.
8. Pharmacovigilance System Compliance
What: Manufacturer has a qualified person responsible for pharmacovigilance (QPPV) and adverse event reporting SOPs.
Verify: Request PV system summary. Mandatory under NDCT Rules 2019 for exporters to regulated markets.
9. Revised Schedule M Compliance (2023 Notification)
What: India’s revised Schedule M (Dec 2023) aligns domestic GMP with WHO-GMP: mandatory ICH Q9 risk management, Pharmaceutical Quality System (PQS), data integrity, validation master plan.
Verify: Ask for the facility’s PQS summary and data integrity policy. Large manufacturers (turnover >₹250 crore) had Dec 2024 deadline; SMEs have until Dec 2025–Jun 2026 (extension debates ongoing per Mint, Dec 2025).
10. IMSDA Membership & Industry Standing
What: IMSDA members maintain valid CDSCO-compliant licenses as a membership condition. Gold members represent the highest compliance tier.
Verify: Check the IMSDA verified member directory. Membership indicates commitment to quality and ethical practices.
📋 Quick-Reference Verification Table
| Check Item | Document to Request | Verifying Authority / Source | Red Flags |
|---|---|---|---|
| Manufacturing License | Form 25/28 copy | State Drug Controller portal | Expired, mismatched address, product not in scope |
| WHO-GMP | Certificate (3-yr validity) | State FDA / WHO prequal list | Expired, limited scope, not on WHO list |
| COPP | Product-specific COPP | State Drug Controller | Missing, expired, product not listed |
| SRA Inspections | EIR / GMP certificate | FDA / EMA / PMDA / TGA databases | OAI classification, Warning Letter, import alert |
| Batch CoA | CoA per batch | Manufacturer QC lab | Missing tests, out-of-spec results, no signatures |
| Stability Data | Protocol + summary | Manufacturer / ICH Q1A | No real-time data, gaps in timeline |
| Schedule M Compliance | PQS summary, DI policy | Facility self-declaration / audit | No PQS, no data integrity controls |
| Pharmacovigilance | QPPV details, SOP | Manufacturer / NDCT Rules | No QPPV, no AE reporting process |
⚠️ Common Pitfalls & How to Avoid Them
- Pitfall: Assuming CDSCO approval = automatic eligibility in your country
Fix: Each country has sovereign approval — verify destination requirements independently - Pitfall: Relying on trader/intermediary documents without verifying the actual manufacturer
Fix: Always trace back to the manufacturing site license; confirm trader’s Form 20B/21B wholesale license and IEC - Pitfall: Accepting a single CoA for multiple batches
Fix: Demand batch-specific CoA for every shipment - Pitfall: Ignoring temperature excursions during transit
Fix: Use data loggers; require cold-chain validation for biologics/insulins - Pitfall: Overlooking the revised Schedule M transition period
Fix: Ask specifically about PQS implementation and data integrity controls — not just “GMP certified”
🔗 Trusted Resources for Ongoing Verification
- WHO Prequalified Medicines: extranet.who.int/prequal
- FDA Establishment Inspection Reports: accessdata.fda.gov/scripts/cder/daf
- EMA GMP Compliance: ema.europa.eu/en/inspections
- CDSCO Official Website: cdsco.gov.in
- Pharmexcil Member Directory: pharmexcil.com
- IMSDA Verified Member Directory: indiamedicine.org/?page_id=1454
📚 Sources
- GTRI — India Supplies 20% of Global Generic Medicines (May 2026)
- CDSCO — Revised Schedule M Notification (Dec 2023) and 2026 Implementation Updates
- Business Standard — CDSCO Tightens Quality Net with Audits, Scientific Cadre Overhaul (Feb 2026)
- Medical Dialogues — CDSCO, DoP Told to Find Workable Solution on Revised Schedule M GMP Concerns (Jan 2026)
- Mint — Govt Mulls Extension for Pharma New Manufacturing Practice Norms (Dec 2025)
- WHO — Guidelines on Good Manufacturing Practices (Technical Report Series)
- ICH Q1A — Stability Testing of New Drug Substances and Products
- ICH Q9 — Quality Risk Management
- NDCT Rules 2019 (Amended 2026) — Pharmacovigilance Requirements for Exporters
For more information, contact IMSDA at contact@indiamedicine.org.